SecBot SecBot
DEFA14A ·Filed Apr 23, 2026

EWTX

Edgewise Therapeutics, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed6mo ago SEC0001104659-26-047691
Proxy solicitation materials
Actionable Insight • Neutral

Monitor the company's upcoming 10-Q for any guidance or financial updates, as this proxy filing contains no new financial information. The vote on executive compensation could be a minor read-through for investor sentiment if there is a significant 'say on pay' dissent, but none is indicated here.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$31.58
T+0 close · Apr 23, 2026 · via day close
Latest settled
+25.33%
T+60 · $39.58
Vs SPY
+20.25%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 24 $31.58entry
  2. T+1 · 7mo ago −2.98%α −3.14% · $30.64
  3. T+5 · 7mo ago −1.96%α −2.87% · $30.96
  4. T+20 · 6mo ago +3.51%α −0.51% · $32.69
  5. T+60 · 4mo ago +25.33%α +20.25% · $39.58
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Edgewise Therapeutics is holding its 2026 Annual Meeting where shareholders are asked to vote on three proposals: electing three director nominees, ratifying KPMG LLP as the independent auditor, and approving the compensation of named executive officers. The filing is a definitive proxy statement filed by the company, indicating standard, routine corporate governance matters.

Key Financial Metrics

Vote
director election
Meeting
2026-06-04

Key Facts

  • The filing is a DEFA14A, a definitive proxy statement for the 2026 Annual Meeting.
  • Three proposals are on the ballot: election of directors (Laura Brege, Badreddin Edris, Jonathan Root), ratification of KPMG LLP as auditors, and an advisory vote on executive compensation.
  • The company is requesting votes by June 3, 2026, for a meeting on June 4, 2026.
  • The filing was made by the registrant (Edgewise Therapeutics, Inc.), not a dissident party.

Financial Impact

No immediate financial impact. This is a routine governance filing.

governanceboard compositionauditor selectionexecutive compensation

Risk Factors

  • Low. The primary risk is a potential 'say on pay' vote failure, which could signal governance concerns, but this is not indicated in the current filing.
  • The routine nature of the proposals means there is minimal risk to the company's operations or stock price from this event.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001104659-26-047691
Document: 0001104659-26-047691-index-headers.html0001104659-26-047691
Document: 0001104659-26-047691-index.html0001104659-26-047691
Document: 0001104659-26-047691.txt0001104659-26-047691

US Market Status

Market Closed · Opens Wed (9h 53m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 23, 2026